Nigel Brooksby

LEO Pharma

Robert Spurr

LEO Pharma has appointed Robert Spurr as executive vice president of North America, and chief executive officer and president of LEO Pharma US. Spurr has most recently been serving as vice president of market access, patient services, sales and health economics and outcomes research at LEO. He previously held senior leadership positions at Novartis and Johnson & Johnson.

Daiichi Sankyo

Hiroyuki Okuzawa

Daiichi Sankyo has appointed Hiroyuki Okuzawa as chief executive officer. Okuzawa first joined the company almost four decades ago and has most recently been serving as representative director, president and chief operating officer. He was also previously chief financial officer and held other senior leadership roles in international business, corporate strategy and human resources.

Antag Therapeutics

Joerg Moeller

Antag Therapeutics has appointed Joerg Moeller as chief executive officer. Moeller has over 30 years of industry experience and joins Antag after serving as chief executive officer and executive director at BenevolentAI. Prior to this, he was corporate executive vice president, head of global research and development at LEO Pharma and spent almost 20 years in roles at Bayer.

BeiGene

Giancarlo Benelli

BeiGene has appointed Giancarlo Benelli as senior vice president and head of Europe. Benelli most recently served as vice president, head radioligand therapy international markets at Novartis. Prior to this, he was general manager at Advanced Accelerators Applications and held roles at AstraZeneca, Schering-Plough Research Institute and IMS Health.

Biogen

Adam Feire

Biogen has appointed Adam Feire as head of business development and external innovation. Feire has nearly two decades of industry experience and most recently served as global head of search and evaluation within Novartis corporate and business development. He held multiple roles at Novartis, including global head of search and evaluation, innovative medicines.

Cardurion Pharmaceuticals

Charlotte Newman

Cardurion Pharmaceuticals has appointed Charlotte Newman as chief business officer. Newman holds over 25 years of industry experience and most recently served as chief business officer of Agios Pharmaceuticals. Prior to Agios, she was vice president and asset executive, Alzheimer’s disease, and vice president, research and development portfolio leadership at Biogen.

Chiesi

Roch Doliveux

Chiesi has appointed Roch Doliveux as non-executive director. Doliveux brings extensive leadership experience in biopharmaceuticals to the board, having served as chief executive officer of UCB for a decade. He was also previously chief executive officer of Pierre Fabre Pharmaceuticals and president of Schering-Plough International.

Chiesi

Paolo Pucci

Chiesi has appointed Paolo Pucci as non-executive director. Pucci joins the company’s board after serving as chief executive officer of ArQule. He also previously held positions of increasing responsibility at Bayer, culminating in his role as president of the company's global oncology and specialty medicine business unit, and served in a number of roles at Eli Lilly earlier in his career.